Embodiment 8 of this disclosure are compounds of Formula I, or any one of Embodiments 1-7 or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 Embodiment 9 of this disclosure are compounds of Formula I, or any one of Embodiments 1-8 or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 28 of this disclosure are compounds of Formula I, or Embodiments 1-12, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 29 of this disclosure are compounds of Formula I, or Embodiments 1-11, 13, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 30 of this disclosure are compounds of Formula I, or Embodiments 1-11, 14, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 31 of this disclosure are compounds of Formula I, or Embodiments 1-11, 14, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 32 of this disclosure are compounds of Formula I, or Embodiments 1-11, 14, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 33 of this disclosure are compounds of Formula I, or Embodiments 1-11, 14, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 34 of this disclosure are compounds of Formula I, or Embodiments 1-11, 14, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 35 of this disclosure are compounds of Formula I, or any one of Embodiments 1-34, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is Embodiment 48 of this disclosure are compounds of Formula I, or any one of Embodiments 1-38 or 47, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is Embodiment 49 of this disclosure are compounds of Formula I, or any one of Embodiments 1-38 or 47, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is Embodiment 50 of this disclosure are compounds of Formula I, I-a, or I-b, or any one of Embodiments 1-38 or 47, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is Embodiment 51 of this disclosure are compounds of Formula I, I-a, or I-b, or any one of Embodiments 1-38 or 47, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is Embodiment 52 of this disclosure are compounds of Formula I, I-a, or I-b, or Embodiments 1-51, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 4 is H
HMGB1, high mobility group B1
When homocysteine is too low, the production of these two heavy hitters drops, which can cause detoxification issues, nerve damage, and immune system struggles
If adding collagen to cold foods and beverages, solubility may become an issue, and additional mixing may be required
